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Abstract
Surgical management of tetralogy of Fallot (TOF) results in anatomic and functional abnormalities in the majority
of patients. Although right ventricular volume load due to severe pulmonary regurgitation can be tolerated for
many years, there is now evidence that the compensatory mechanisms of the right ventricular myocardium
ultimately fail and that if the volume load is not eliminated or reduced by pulmonary valve replacement the
dysfunction might be irreversible. Cardiovascular magnetic resonance (CMR) has evolved during the last 2 decades
as the reference standard imaging modality to assess the anatomic and functional sequelae in patients with
repaired TOF. This article reviews the pathophysiology of chronic right ventricular volume load after TOF repair and
the risks and benefits of pulmonary valve replacement. The CMR techniques used to comprehensively evaluate the
patient with repaired TOF are reviewed and the role of CMR in supporting clinical decisions regarding pulmonary
valve replacement is discussed.
Introduction
Although the management of tetralogy of Fallot (TOF)
has evolved considerably since Blalock and Taussig
described the first systemic artery-to-pulmonary artery
shunt in 1945 and Lillehei and Varco reported the first
repair by an open-heart procedure in 1954 [1-3], opti-
mal surgical repair has remained elusive. While early
surgical mortality decreased from 50% in the late 1950’s
to less than 2% in the modern surgical era [4-7], residual
anatomic and hemodynamic abnormalities are nearly
universal. As a result, the number of patients with
repaired TOF, many of whom with considerable cardiac
and non-cardiac disease burden, is growing rapidly [8,9].
Right ventricular (RV) dilation from pulmonary regur-
gitation (PR), residual atrial and/or ventricular septal
defect, tricuspid regurgitation, right ventricular outflow
tract (RVOT) aneurysm, pulmonary artery stenosis, and
tachyarrhythmias are some of the abnormalities fre-
quently encountered in patients with repaired TOF.
Although the hemodynamic burden associated with these
anomalies is often tolerated well during childhood and
adolescence, the incidences of arrhythmias, exercise intol-
erance, heart failure, and death nearly triple during the
third postoperative decade and afterward [8-13]. Severe
chronic PR–considered an important, treatable cause of
RV dilatation and failure–has been the focus of many
investigations in recent years. However, despite a growing
body of literature on the management of severe PR after
TOF repair, debate regarding the indications, methods,
and optimal timing of pulmonary valve replacement (PVR)
has persisted [14-17]. Cardiovascular magnetic resonance
(CMR) has emerged as an essential diagnostic tool in this
patient population because it overcomes many of the lim-
itations of echocardiography, cardiac CT, and cardiac
catheterization, while also providing unique quantitative
data as well as prognostic information.
This article comprises two parts. The first part reviews
the pathophysiology, natural history, and clinical chal-
lenges late after TOF repair. The second part discusses the
role of CMR in clinical decision making with an emphasis
on its role in supporting patient selection for PVR.
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Pulmonary Regurgitation After TOF Repair
Relief of RVOT obstruction in TOF often involves dis-
ruption of pulmonary valve integrity, which leads to PR
in the majority patients. Both experimental evidence and
clinical data have shown that the severity of PR can
increase over time [18-20]. The degree of PR is deter-
mined by (1) regurgitation orifice area; (2) RV compli-
ance; (3) diastolic pressure difference between the main
pulmonary artery (MPA) and the RV; (4) capacitance of
the pulmonary arteries; and (5) duration of diastole.
Some of the key factors influencing PR volume are cap-
tured by the Torricelli principle [21]:
PR volume ROA C DT P P 21
5 =−   ()
. 0
Where ROA = regurgitation orifice area; C = constant
(empiric number); DT = diastolic time; (P2 -P 1) = mean
diastolic pressure difference between the MPA and RV.
Unlike aortic regurgitation, the diastolic pressure differ-
ence between the MPA and the RV is small. Therefore,
the PR volume is largely determined by other factors,
namely the size of the regurgitation orifice (typically
large after TOF repair), the capacitance of the pulmon-
ary arteries [22], and duration of diastole (related to
heart rate). Other factors such as pulmonary vascular
resistance and LV function may also influence PR.
At the time of TOF repair, the RV is hypertrophied
and its compliance is low; the diameters of the central
pulmonary arteries are either hypoplastic or low-normal,
and their capacitance is low; and the heart rate is rela-
tively high, which leads to a relatively short duration of
diastole. Therefore, despite a relatively large regurgita-
tion orifice immediately after TOF repair, the combina-
tion of factors described above minimizes the impact of
PR. Over time, however, the increase in RV stroke
volume leads to progressive rise in the size and capaci-
tance of the central pulmonary arteries and to RV dila-
tation. Combined with a longer duration of diastole as
heart rate decreases with age, these changes lead to pro-
gressive increase in the degree of PR (Figure 1). Experi-
mental evidence supporting this progression was
provided by Kuehne et al. who demonstrated in growing
swines with a stented pulmonary valve an increase in
PR fraction from 33 ± 7% at baseline to 49 ± 6% at
3 months [19]. Progression of PR, however, likely pla-
teaus at some point but quantitative longitudinal data
documenting this assumption is lacking.
Effects of Chronic Volume Load on Ventricular Mechanics
A growing clinical experience and experimental evidence
point to striking similarities between the pathophysiolo-
gic response of the left and right ventricles to severe
chronic volume load. Moreove r ,i n - v i t r os t u d i e sh a v e
shown similar intrinsic properties of myofibers from the
left and right ventricles, including their response to
pressure and volume overload conditions [23,24].
Because the pathophysiology of left ventricular (LV)
response to chronic aortic regurgitation has been stu-
died in great detail [25-27], it is worth considering the
sequence of events here. Investigators divide the patho-
physiologic response of the LV to severe chronic aortic
regurgitation into 4 stages of variable duration: 1) A
compensated stage characterized by an increase in end-
diastolic volume and a combination of eccentric and
concentric hypertrophy. At the cellular level, ventricular
dilatation is characterized by cellular elongation, addi-
tion of myofibers, and a decrease in collagen content. At
the pump level, these changes lead to an increase in
end-diastolic volume and maintenance of relatively nor-
mal mass-to-volume ratio (compensated hypertrophy),
end-systolic fiber stress, and global systolic function. An
increase in stroke volume maintains net forward flow
within normal limits. This stage may last for many
years or even decades. 2) Failure of compensatory
mechanisms. This stage is characterized by continued
LV dilatation but with decreased mass-to-volume ratio
(inadequate hypertrophy) and increased afterload (end-
systolic stress). As a result, the rate and magnitude
of fiber shortening decrease. This stage manifests
as decreased global systolic function while intrinsic
myocardial contractility remains relatively normal.
Figure 1 Some of the factors influencing progression of
pulmonary regurgitation after TOF repair. This process likely
plateaus at a certain point but the time course of PR has not been
fully characterized.
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the short term, the impaired contractility may be rever-
sible, and elimination of the volume load can result in
recovery of pump function. 4) Irreversible myocardial
injury associated with fibrosis and increased interstitial
collagen [28]. Although valve replacement may still be
tolerated and of clinical benefit [27,29], myocardial dys-
function persists.
Similar to the above-described course of LV response
to volume load, patients usually tolerate chronic RV
volume load without symptoms for many years. Indeed
some investigators in the 1970s and 1980s considered
PR benign [30]. Isolated congenital PR–a rare cardiac
anomaly similar to TOF with absent pulmonary valve
syndrome but without ventricular septal defect–offers a
unique opportunity to examine the long-term effects of
severe chronic PR without the confounding effects of
cyanosis, ventricular septal defect, pulmonary stenosis,
or the sequelae of cardiac surgery. In a review of 72
such cases reported in the literature [31], Shimazaki
et al. found that that the annualized probability of devel-
oping symptoms of heart failure increased exponentially
over time, mostly after age 40 years. Similarly, studies of
patients with a secundum atrial septal defect, which also
results in isolated RV volume overload, have demon-
strated that the volume load adversely affects both right
and left ventricular geometry and function and that
these abnormalities are fully reversible when the shunt
is eliminated early in life [32-36]. However, functional
recovery is less complete when an atrial septal defect is
closed later in life [37-39]. Taken together, these studies
show that “isolated” RV volume load can be tolerated
with little or no symptoms during the first 3-4 decades
of life and elimination of the volume load during that
period usually leads to full functional recovery. Left
untreated, however, continued RV volume load is asso-
ciated with an accelerated rate of progressive symptoms
and incomplete functional recovery of RV systolic and
diastolic function.
RV Mechanics After TOF Repair
Although the pathophysiology of RV remodeling in
response to the altered hemodynamic conditions after
TOF repair is strikingly similar to the response of the
LV to chronic volume load, important differences exist.
Examples include chamber geometry, myofiber architec-
ture, chamber contraction pattern, coronary artery anat-
omy and flow dynamic, disposition of the conduction
system, and dependency on LV size and function [40].
The RV comprises two distinct embryologic compo-
nents–the sinus and the infundibulum–with a complex
shape. The myocardium comprises a relatively thin
compact layer and a prominent layer of trabeculations
interspersed with deep recesses. In contrast to the LV,
the orientation of the myofibers in the RV is more
horizontal and contraction is predominantly from
base-to-apex (longitudinal) with a lower degree of
angular motion (twist). The myocardium is supplied by
as i n g l ec o r o n a r ya r t e r yw i t hn e a r l y5 0 %o ft h ef l o w
occurring during diastole under normal conditions as
oppose to ~90% in the LV. The conduction system in
t h eR Vc o m p r i s e sas i n g l ef a s c i c l ew i t hal o n gc o u r s e
and a long delay in activation between the base and
the distal infundibular free wall, resulting in peristalsis-
like motion [41]. Although RV function impacts
LV function, the reverse is much more pronounced
with 63% of RV pressure rise accounted for by LV
contraction.
After TOF repair, additional factors related to the
operation further impact the pathophysiology. Relief of
RV outflow obstruction typically involves incision of the
infundibular free wall, resection of obstructive muscle
bundles, disruption of the pulmonary valve with partial
or complete excision, and placement of an outflow
patch, which often extends across the plane of the pul-
monary valve into the MPA. In some patients a conduit
between the RV and the pulmonary arteries is required
to provide antegrade pulmonary blood flow. The ventri-
cular septal defect is closed with a patch, a procedure
that can impair tricuspid valve function. In addition to
the nearly universal occurrence of PR (discussed above),
these procedures often lead to akinesis or dyskinesis of
the RVOT, outflow patch aneurysm (Figure 2), fibrosis
of the RV free wall, and conduction delay [42]. Table 1
Figure 2 Steady-state free precession cine CMR of the right
ventricular (RV) inflow and outflow showing a large outflow
tract patch aneurysm (An). RA = right atrium.
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after TOF repair.
Studies in animal models of RV volume load similar to
conditions seen after TOF repair provide insight into
myocardial adaptation. Kiriazis et al. studied an in-vitro
preparation of RV papillary muscle subjected to volume
load [43]. They showed that peak stress development
and other markers of myocardial mechanics and energy
were normal in a stage of compensated hypertrophy but
reduced in uncompensated volume load. Kuehne et al.
used CMR and conductance catheter techniques to
investigate the effects of PR on biventricular mechanics
in a growing swine model [19]. Compared with control
animals, indices of RV systolic function (ejection frac-
tion, peak dP/dt, and Emax) were significantly reduced 3
months after induction of PR.
Human studies in repaired TOF patients using CMR
provide insights regarding ventricular mechanics and
clinical outcomes in this population [10,44-47]. Several
authors have demonstrated a close relationship between
the degree of PR and RV diastolic dimensions and
stroke volume (Figure 3) [48-51]. Similar to LV function
in severe chronic aortic regurgitation, once the compen-
satory mechanisms of the RV fail, mass-to-volume ratio
decreases, end-systolic volume increases, and ejection
fraction decreases (Figure 4). Kurotobi et al. demon-
strated an association between an increase in RV wall
stress (afterload), decreased RV ejection fraction, and
symptoms in patients with repaired TOF [52]. Other
factors that adversely affect RV mechanics include the
spatial extent and magnitude of dyskinesis of the out-
flow patch (Figure 5), [19,42] RV fibrosis [42,45,53],
impaired RV diastolic function, [49,54-58] and left ven-
tricular dysfunction [10,45,59-61]. Prolonged conduction
time and dyssynchrony of RV contraction likely further
contribute to RV dysfunction. An older age of repair is
another independent risk factor for adverse outcome in
these patients [10,13,62]. Similar to the natural history
of severe aortic regurgitation, in which irreversible myo-
cardial damage follows a period of reversible ventricular
Table 1 Structural and functional abnormalities encountered in repaired TOF
Structural Abnormalities Functional Abnormalities
Inherent to TOF repair RV volume overload
Partial or complete removal of pulmonary valve tissue Pulmonary regurgitation
Infundibulotomy scar Tricuspid regurgitation
Resection of RV/infundibular muscle bundles Left-to-right shunt
Right atriotomy scar Ventricular septal defect
VSD patch Atrial septal defect
Residual or recurrent lesions Aorto-pulmonary collaterals
RV outflow tract obstruction RV pressure overload
Main or branch pulmonary artery stenosis RV outflow or pulmonary artery stenosis
Ventricular septal defect Pulmonary vascular disease
Atrial septal defect Pulmonary venous hypertension secondary to LV dysfunction
Acquired lesions RV systolic dysfunction
Tricuspid valve abnormalities RV diastolic dysfunction
RV outflow tract aneurysm LV dysfunction
RV fibrosis Ventricular conduction delay
Associated anomalies Arrhythmias
Dilated aorta Atrial flutter
Associated congenital cardiovascular anomalies Atrial fibrillation
Associated genetic and non-cardiac anomalies Ventricular tachycardia
Co-morbidities
Renal, pulmonary, musculoskeletal, neurodevelopmental abnormalities
Figure 3 Correlation between pulmonary regurgitation and
right ventricular (RV) end-diastolic volume index in 206
patients with repaired TOF [46].
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after TOF repair [15,63]. Figure 6 summarizes the
pathophysiologic pathway that leads to ventricular dys-
function and heart failure after TOF repair.
RV-LV Interaction After TOF Repair
The right and left ventricles function in series and, in
the absence of shunts, have similar net outputs. In 1910
the French physiologist Bernheim first recognized inter-
dependence between LV and RV function. He postu-
lated that alterations in the size and function of the LV
adversely impact the geometry and function of the RV, a
phenomenon termed ‘Bernheim effect’ [64]. Many sub-
sequent studies have demonstrated that alterations in
the size and function of the RV lead to LV dysfunction,
a phenomenon termed ‘reversed Bernheim effect’ [65].
Ventricular-ventricular interaction occurs because the
ventricles share myofibers [66], septum, coronary blood
Figure 4 Relationship between right ventricular end-systolic
volume and RV ejection fraction in 100 patients with repaired
TOF (Spearman rank correlation coefficient (rs) = -0.77; p <
0.001) [10].
Figure 5 Three-dimensional surface models of the right ventricular (RV) free wall reconstructed from multi-slice 2-dimensional short-
and long-axis images. Top panel: Scar tissue map based on late gadolinium enhancement (LGE) imaging showing extensive late
hyperenhancement of the RVOT (yellow and orange). Bottom panel: Displacement map based on multi-slice cine SSFP showing dyskinesis of the
RVOT (red). See Wald et al. for further technical details [42].
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layer of RV myofibers is continuous with the superficial
layer of the LV whereas the deep layer of RV myofibers
is continuous with that of the LV through the interven-
tricular septum.
The adverse impact of RV dilatation and dysfunction
on LV geometry and function (both diastolic and systolic)
h a sb e e nd e m o n s t r a t e di np a t i e n t sw i t hc o n g e n i t a l( e . g . ,
atrial septal defect, Ebstein anomaly) and acquired heart
disease (e.g., pulmonary embolus, primary pulmonary
hypertension). Through a complex interplay involving
the shared myofibers, septum, pericardium, and coronary
flow, RV volume load leads to septal shift towards the
LV, leftward shift of the LV pressure-volume loop, and
reduction in LV operant volumes. Initially, LV function is
preserved but with progressive RV dysfunction, LV func-
tion deteriorates. Ventricular dyssynchrony, both intra-
and inter-ventricular, likely contribute to adverse RV-LV
interaction [60,67]. In the previously mentioned study of
Kuehne et al. [19], the response of both the RV and LV
to dobutamine stress was markedly blunted, suggesting
that LV function is adversely influenced by impaired RV
mechanics. A clinical study using CMR in patients with
repaired TOF demonstrated a close linear correlation
between the ejection fraction of the RV and that of the
LV (Figure 7) [10].
Natural History And Outcomes After Tof Repair
Early survival of patients with TOF is excellent with
1-2% operative mortality [68,69]. Two large cohort
studies of patients with repaired TOF have shown that
survival continues at ~90% during the first two
decades of life [8,9]. However, mortality rate nearly tri-
ples during the third postoperative decade. Numerous
studies have shown that late after TOF repair patients
are at risk for exercise intolerance, heart failure,
arrhythmias, and death [10,47,70-79]. In addition, pul-
monary, renal, hepatic, musculoskeletal, and other
non-cardiac morbidities often complicate the clinical
course of these patients [47].
The common theme that has emerged from the litera-
ture on risk stratification of major adverse events (death,
ventricular tachycardia, and heart failure) late after TOF
repair is that there are 3 major categories of outcome
predictors: 1) history (syncope, older age at repair);
2) electrophysiological markers (prolonged QRS dura-
tion, sustained ventricular tachycardia); and 3) hemody-
namic sequelae of severe PR (RV dilatation, ventricular
dysfunction, and regional wall motion abnormalities).
Multiple studies have addressed risk factors for sud-
den death and for tachyarrhythmias late after TOF
repair. Gatzoulis et al. studied 793 patients from 6 cen-
ters [80]. They found that an older age at repair and
QRS duration ≥180 ms were independent predictors of
sudden death. Moderate or severe PR was the main
hemodynamic abnormality in patients with ventricular
tachycardia and sudden death, whereas tricuspid regur-
gitation was associated with supraventricular arrhyth-
mias. Khairy et al., in a multicenter study of 252
patients with repaired TOF, found that a positive pro-
grammed ventricular stimulation study, history of syn-
cope, moderate or severe pulmonary or tricuspid
regurgitation, QRS duration ≥180 ms, cardiomegaly on
chest radiogram (cardio-thoracic ratio ≥0.6), and multi-
focal premature ventricular contractions were associated
with sudden death or clinical ventricular tachycardia
[79]. Harrison et al. found that patients with sustained
Figure 6 Factors influencing right ventricular (RV) dysfunction
and impaired clinical status after TOF repair.
Figure 7 Association between right ventricular (RV) and left
ventricular (LV) ejection fraction (EF) in 100 patients with
repaired TOF [10].
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aneurysms and severe PR [81]. Ghai et al., in a study
that compared 12 adult patients who died late after
TOF repair to 125 control patients, found that patients
w h od i e dw e r em o r el i k e l yt oh a v eh i s t o r yo fs u s t a i n e d
ventricular tachycardia, prolonged QRS duration ≥180
ms, moderate or severe PR, and moderate or severe left
ventricular dysfunction [59]. It is worth noting that
in none of these studies was RV size or function
quantified.
In a study that used CMR to measure PR and biven-
tricular dimensions and function in 100 late survivors of
TOF repair, RV and LV dysfunction were strongly asso-
ciated with impaired clinical status, but the degree of PR
w a sn o t[ 1 0 ] .I n s t e a d ,t h es e v e r i t yo fP Rw a sm a i n l y
related to the degree of RV enlargement, a finding that
concurs with other studies that utilized CMR to assess
these variables [49,82]. Knauth et al., in a follow-up
study of the previous cohort, found that severe RV dila-
tation (end-diastolic volume Z-score ≥7m e a s u r e db y
CMR) and ventricular dysfunction (LV EF <55% or RV
EF <45%) were independent predictors of adverse out-
comes (death, sustained ventricular tachycardia, heart
failure) [47]. Other univariate predictors were older age
at TOF repair and QRS duration ≥180 ms. Importantly,
QRS duration correlated closely with RV end-diastolic
volume and, therefore, lost statistical significance in a
multivariate model. Other investigators have also
reported a similarly close association between QRS
duration and RV size [83,84]. Myocardial fibrosis,
RVOT aneurysm, and regional wall motion abnormal-
ities have also been associated with symptoms, exercise
intolerance, and arrhythmias [42,45,53,85].
Treatment Strategies Late After Tof Repair
Indications and Timing of Pulmonary Valve Replacement
Recommendation for PVR in patients with repaired
TOF and severe PR are based on risk/benefit analy-
sis that takes into account the natural history and
pathophysiology of the disease, procedural risks, and its
potential benefits.
Risks of Pulmonary Valve Replacement
The operative mortality for surgical PVR is low
( T a b l e2 ) .T h e r ei s ,h o w e v e r ,c o n t i n u e dl o wr i s ko f
death after PVR. Therrien et al. reported 92% survival at
5 years and 86% at 10 years in 70 adult patients after
PVR [86]. Discigil et al. reported 95% survival at 5 years
and 76% at 10 years in 42 patients [87]. Harrild et al.
followed 98 patients after PVR (age at PVR 25 ±
13 years). Freedom from death and/or ventricular tachy-
cardia was 80% at 5 years and 41% at 10 years, and the
event incidence was 4.8 per 100 patient-years [88].
When considering the risks associated with PVR, the
risk of valve failure should also be considered. All
Table 2 Perioperative and late mortality of pulmonary valve replacement after TOF repair
Institution Year Number of
Patients
Operative
Death
Average Length
of Follow-Up
(years)
Late Death
or
transplant
SUNY, Syracuse [142] 1985 11 0 1 0
Children’s Memorial Hospital,
Chicago [143]
1997 49 1
University of Toronto [101] 1997 85 1 5.8 3
Mayo Clinic [87] 2001 42 1
Children’s Hospital, Atlanta [144] 2002 100 1 4.9 1
Leiden University, The Netherlands
[97]
2002 26 0 1.5 1
New England Med Center, Boston
[105]
2003 36 0 5 1
University of Zurich, Switzerland
[100]
2005 39 0 1.25 0
Multicenter, The Netherlands [145] 2006 158 0 4.2 2
University of Toronto [99] 2007 82 0 8.8 2
University Medical Center,
Rotterdam [14]
2008 17 0 6.4 0
International Society of Congenital
Heart Disease [107]
2008 93 0 3 2
Great Ormond Street, London[94] 2008 71 0 1 0
Emory University [146] 2009 107 3
Children’s Hospital Boston [88] 2009 77 0 2.8 6
Children’s Hospital, Atlanta [147] 2010 42 0 2.2 0
1035 0.68% 2.2%
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ited life expectancy, with wide variations in rates of
freedom from valve failure and reoperation, depending
of the type of valve and patient age. Calderone et al.
reported freedom from reoperation in 81% of patients
at 5 years, 58% at 10 years, and 41% at 15 years [89].
These authors, as well as many others, have shown
that young age at pulmonary valve placement is asso-
ciated with a higher rate of valve failure and early
reoperation.
The advent of transcatheter pulmonary valve implan-
tation [90,91], however, may provide a new non-surgical
option for the treatment of failed bioprosthetic pulmon-
ary valve. Although the currently available catheter-
delivered, stent-mounted valves are limited by the size
and geometry of the RVOT to mostly patients with
RV-to-pulmonary artery conduits, future developments
will likely expand the clinical application of this techni-
que to patients with dilated RVOT. Even with currently
available technology, catheter-based pulmonary valve
implantation can be performed inside a failing biopros-
thetic valve or conduit [92]. Further development of this
technology may reduce the need for reoperation after
pulmonary valve implantation and will likely lower the
threshold for restoring pulmonary valve competency in
patients with chronic PR.
Benefits of Pulmonary Valve Replacement
There is strong evidence that PVR is highly effective in
eliminating or greatly reducing PR [93-95]. Multiple stu-
dies published during the past decade have painted a
consistent picture regarding the clinical response and
the mechanical adaptation of the right and left ventricles
to PVR [96]. Table 3 summarizes findings from 10
representative studies. Clinically, many patients report
less cardiac symptoms after PVR and several studies
have reported a significant improvement in NYHA func-
tional class [15,93-95,97-99]. Within approximately one
year after PVR RV end-diastolic and end-systolic
volumes decrease by 30-40% as compared with their
preoperative values. On average, global RV systolic func-
tion (measured as ejection fraction) remains unchanged.
LV end-diastolic volume increases slightly whereas
global LV systolic function remains unchanged
[15,16,63,86,87,95,100-103]. The degree of tricuspid
valve regurgitation (evaluated by Doppler echocardiogra-
phy) tends to improve with or without concomitant tri-
cuspid valve surgery. The percent of patients with at
least moderate tricuspid regurgitation decreased from
25% before PVR to 5% after surgery in the study of Bue-
chel et al. [16], from 24% to 0% in the study of Therrien
et al. [15], and from 13% to 2% in the study of Geva
et al [95].
The data regarding the effects of PVR on QRS dura-
tion, arrhythmia propensity, and objective exercise
parameters is inconsistent. Some investigators have
reported modest improvements in one or more of these
categories whereas others have shown no significant
change from pre- to post-PVR. Therrien et al. reported
that the incidence of ventricular tachycardia was lower
after PVR (9% post operatively versus 23% preopera-
tively) and that the rate of increase in QRS duration had
stabilized after the procedure [86]. In contrast, Harrild
et al. and Gengsakul et al. found no significant improve-
ment in the frequency of arrhythmias after PVR [88,99].
Similarly conflicting results have been reported regard-
ing decrease in QRS duration from pre- to post-PVR
[16,84,88, 95,104]. Finally, whereas some investigators
have reported that certain indices of exercise tolerance
improve [94,102,105], others have not found such
improvement [95,106].
Rationale and Timing of Pulmonary Valve Replacement
Although conclusive confirmation that PVR improves
survival late after TOF repair is still lacking, a growing
b o d yo fe v i d e n c eh a se m e r g e dd u r i n gt h el a s td e c a d e
supporting the rationale for the procedure. There is
strong evidence that without intervention severe PR in
repaired TOF leads to severe RV dilatation and dysfunc-
tion, tricuspid valve regurgitation, LV dysfunction,
tachyarrhythmias, diminished exercise tolerance,
heart failure symptoms, and death (Additional file 1)
[8-10,59,80]. As discussed above, PVR leads to elimina-
tion or marked reduction of PR, improved biventricular
mechanics, improvement in tricuspid regurgitation, and
symptomatic improvement. For many years most centers
have referred patients with severe chronic PR for PVR
based on overt symptoms, such as progressive exercise
intolerance, heart failure symptoms, syncope, or ventri-
cular tachycardia [17,63,88,107]. Recent evidence clearly
demonstrates that relying on symptoms as the major
criteria for PVR results in patients receiving a pulmon-
ary valve when their RV is markedly dilated (mean RV
end-diastolic volume 201 ± 37 ml/m
2 in one study [95]),
and RV and/or LV dysfunction is present (Figure 8).
Several studies have identified pre-PVR threshold values
of RV end-diastolic and end-systolic volumes that are
associated with postoperative normalization of RV size.
Therrien et al. reported that RV size did not return to
normal in any of the 7 patients whose pre-operative
end-diastolic volume index was >170 ml/m
2,w h e r e a s
RV size normalized in 9 of 10 patients with pre-opera-
tive end-diastolic volume ≤170 ml/m
2 [15]. Oosterhof
et al. identified RV end-diastolic volume <160 ml/m
2
and end-systolic volume <82 ml/m
2 as associated with
normal postoperative RV size [93]. Buechel et al. identi-
fied RV end-diastolic volume <150 ml/m
2 as the thresh-
old value below which RV size returns to the normal
range after PVR [16]. Frigiola et al. have adopted an
institutional policy of recommending PVR in
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 8 of 24Table 3 Effects of pulmonary valve replacement on ventricular mechanics, QRS duration, peak oxygen consumption, and functional class
PR (%) RVEDVi
(ml/m
2)
RVESVi
(ml/m
2)
RV EF (%) LVEDVi
(ml/m
2)
LV EF (%) QRS duration
(ms)
Peak O2
consumption
(ml/kg/min)
NYHA class
Before After Before After Before After Before After Before After Before After Before After Before After Before After
Vliegen et al. [97]
N=2 6
Age: 29 ± 9 years
46 ±
10
4±
8
167 ±
40
114 ±
35
99 ± 36 66 ±
35
42 ±
10
42 ±
11
86 ±
29
87 ±
17
2.0 ± 0.6 1.3 ± 0.5
Therrien et al. [15]
N=1 7
Age: 32 years
163 ±
34
107 ±
26
109 ±
27
69 ±
22
32 ± 7 34 ±
10
2.0 ± 1.0 1.4 ± 0.5
van Straten et al.
[148]
N=1 6
Age: 29 years
48 ±
10
3±
5
164 ±
43
113 ±
26
94 ± 33 61 ±
18
44 ± 8 47 ±
12
Doughan et al. [84]
N=2 1
Age: 34 ± 9 years
153 ± 34 142 ± 29
Buechel et al. [16]
N=2 0
Age: 14 ± 3 years
49 ±
14
9±
8
190 ±
33
109 ±
26
102 ±
27
58 ±
16
47 ± 7 45 ± 9 77 ±
10
84 ±
12
53 ± 6 56 ±
7
150 ± 18 148 ± 17
Henkens et al. [98]
N=2 7
Age: 31 ± 8 years
48 ±
11
166 100 98 58 42 ±
10
43 ±
10
89 ±
31
87 ±
18
56 ±
12
55 ±
9
2.0 ± 0.6 1.3 ± 0.3
Oosterhof et al.
[93]
N=7 1
Age: 29 years
44 ±
13
5±
9
171 ±
44
119 ±
34
102 ±
38
70 ±
29
42 ±
10
43 ±
10
85 ±
22
94 ±
20
52 ± 9 53 ±
8
155 ± 29 144 ± 29 53% grade
≥II
11% grade
≥II
Gengsakul et al.
[99]
N=8 2
Age: 28 ± 13 years
164 ± 21 168 ± 21 54% grade
≥II
13% grade
≥II
Frigiola et al. [94]
N=7 1
Age 22 ± 11 years
41 ± 9 5 ±
7
142 ±
43
91 ± 18 73 ± 33 43 ±
14
51 ±
10
54 ± 7 66 ±
12
73 ±
13
61 ± 8 64 ±
7
25 ± 10 25 ± 9 2.0 1.0
Geva et al. [95]
N=6 4
Age: 21 years
49 ±
11
5±
9
201 ±
37
123 ±
25
107 ±
29
68 ±
24
47 ± 8 45 ± 9 89 ±
15
94 ±
17
58 ± 8 57 ±
7
154 (82-
200)
150 (80-
202)
26.5 (8-
47)
27 (10-
48)
47% grade
≥II
8% grade
≥II
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4asymptomatic patients based on RV dilatation (RV/LV
ratio >2) and abnormal exercise test results [94]. With
an average preoperative RV end-diastolic volume of
142 ± 43 ml/m
2,R Ve n d - s y s t o l i cv o l u m eo f9 1±1 8
ml/m
2, and RV ejection fraction 47 ± 8%, RV size and
function was, on average, within normal limits one year
after PVR. The authors, therefore, recommend PVR
before RV end-diastolic volume exceeds 150 ml/m
2.
We analyzed pre-PVR predictors of normal post-PVR
RV size (end-diastolic volume index ≤114 ml/m
2)a n d
function (ejection fraction ≥48%) in 64 patients with
severe chronic PR [95]. Independent predictors of nor-
mal RV size and function were pre-operative RV end-
systolic volume index <90 ml/m
2 and QRS duration
<140 ms.
Thus, the timing and indications for PVR after TOF
repair must balance the benefits of elimination
of RV volume load before irreversible dysfunction
occurs and the disadvantages of a premature surgical
or transcatheter procedure. As with any other medical
procedure, the risks and benefits of the procedure
must be weighed on a case-by-case basis, taking into
account not only cardiac risk factors but also the risks
associated with non-cardiac morbidities. With the
above considerations in mind, the following sum-
marizes the author’s current recommendations for
PVR in patients with repaired TOF or similar physiol-
ogy. These recommendations will undoubtedly con-
tinue to evolve as new information becomes available
and as valve technology and implantation methods
continue to improve.
Indications for Pulmonary Valve Replacement
Indications for PVR in patients with repaired TOF or
s i m i l a rp h y s i o l o g yw i t hm o d e r a t eo rs e v e r ep u l m o n a r y
regurgitation (regurgitation fraction ≥25%):
I. Asymptomatic patient with two or more of the fol-
lowing criteria a. RV end-diastolic volume index
>150 ml/m
2 or Z-score >4. In patients whose body
surface area falls outside published normal data:
RV/LV end-diastolic volume ratio >2
b. RV end-systolic volume index >80 ml/m
2
c. RV ejection fraction <47%
d. LV ejection fraction <55%
e. Large RVOT aneurysm
f. QRS duration >140 ms
g. Sustained tachyarrhythmia related to right heart
volume load
h. Other hemodynamically significant abnormalities:
○ RVOT obstruction with RV systolic pressure
≥2/3 systemic
○ Severe branch pulmonary artery stenosis (<30%
flow to affected lung) not amenable to transcath-
eter therapy
○ ≥ Moderate tricuspid regurgitation
○ L e f t - t o - r i g h ts h u n tf r o mr e s i d u a la t r i a lo r
ventricular septal defects with pulmonary-to-
systemic flow ratio ≥ 1.5
○ Severe aortic regurgitation
○ Severe aortic dilatation (diameter ≥5 cm)
II. Symptomatic Patients Symptoms and signs attribu-
table to severe RV volume load documented by CMR or
alternative imaging modality, fulfilling ≥1o ft h eq u a n t i -
tative criteria detailed above. Examples of symptoms
and signs include
a. Exercise intolerance not explained by extra-cardiac
causes (e.g., lung disease, musculoskeletal anomalies,
genetic anomalies, obesity), with documentation by
exercise testing with metabolic cart (≤70% predicted
peak VO2 for age and gender not explained by
chronotropic incompetence)
b. Signs and symptoms of heart failure (e.g., dyspnea
with mild effort or at rest not explained by extra-
cardiac causes, peripheral edema)
c. Syncope attributable to arrhythmia
III. Special considerations a. Due to higher risk of
adverse clinical outcomes in patients who underwent
TOF repair at age ≥3 years [10], PVR may be consid-
ered if fulfill ≥1 of the quantitative criteria in section I
b. Women with severe PR and RV dilatation and/or
dysfunction may be at risk for pregnancy-related
complications [108]. Although no evidence is avail-
able to support benefit from pre-pregnancy PVR, the
procedure may be considered if fulfilling ≥1o ft h e
quantitative criteria in section I
Role of CMR
Because it is not limited by acoustic window, not asso-
ciated with exposure to ionizing radiation, and is nonin-
vasive, CMR is ideally suited for longitudinal follow-up in
patients with repaired TOF [109]. Since it provides accu-
rate quantitative informationo nb i v e n t r i c u l a rs i z ea n d
function, blood flow measurements, myocardial viability,
and cardiovascular anatomy, in many centers CMR has
become the preferred method of noninvasive imaging in
patients with repaired TOF [10,45,50,54,97,110-113]. At
Children’s Hospital Boston, postoperative TOF is the
most common diagnosis in patients referred for CMR,
accounting for ~23% of patients. However, comprehen-
sive assessment of the patient with repaired TOF requires
integration of information from clinical assessment
(detailed history and physical examination) and labora-
tory investigations (ECG, Holter monitor, exercise test,
and echocardiography). Computed tomography and
radionuclear studies can be used when CMR is contrain-
dicated or not available. Cardiac catheterization (with or
without electrophysiological testing) is indicated in
selected patients [17,95,114].
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The goals of CMR in patients with repaired TOF
include:
￿ Quantitative assessment of left and right ventricu-
lar volumes, mass, stroke volumes, and ejection
fraction.
￿ Evaluation of regional wall motion abnormalities.
￿ Imaging the anatomy of the right ventricular
outflow tract, pulmonary arteries, aorta, and aorto-
pulmonary collaterals.
￿ Quantification of PR, tricuspid regurgitation,
cardiac output, and pulmonary-to-systemic flow
ratio.
￿ Assessment of myocardial viability with particular
attention to scar tissue in the ventricular myocar-
dium aside from sites of previous surgery (e.g.,
ventricular septal defect and RVOT patches).
Study Protocol
￿ The importance of careful attention to details of
patient preparation and placement in the scanner
cannot be overemphasized. Optimal placement of
ECG leads is paramount to quality gating. A per-
ipheral intravenous cannula for injection of gadoli-
nium-based contrast is placed in the following
circumstances:
1. First CMR examination
2. >3 years since last late gadolinium enhance-
ment (LGE) evaluation
3. Deterioration in clinical status
4. Regional or global ventricular function has
worsened
Exceptions are made in young patients when place-
ment of an intravenous cannula might result in loss of
patient cooperation.
Imaging protocol
￿ Localizing images: ECG-gated steady-state free
precession (SSFP) localizing imaging in the axial,
coronal, and sagittal planes followed by real-time
interactive sequences for identification of key ima-
ging planes and structures targeted for additional
sequences (e.g., ventricular long- and short-axis
planes, short-axis of the proximal MPA for subse-
quent measurements of PR).
Figure 8 CMR imaging in a 37 year-old patient with repaired TOF, severe pulmonary regurgitation, moderate tricuspid regurgitation
(arrow), and severe right ventricular dilatation (end-diastolic volume index 386 ml/m
2) and dysfunction (ejection fraction 15%). This
patient who also exhibited severe heart failure symptoms had only modest decrease in RV size and no improvement in RV function after
pulmonary valve replacement.
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lowing planes:
▪ LV 2-chamber (Figure 9)
▪ RV 2-chamber (Figure 10)
▪ 4-chamber (4 slices) (Figure 11)
▪ Ventricular short-axis (Figure 12). The latter
is achieved by prescribing 12-14 equidistant slices
(slice thickness 6-8 mm; inter-slice space 0-2 mm)
covering the entire length of both ventricles. Parti-
cular attention is given to inclusion of the base of
the RV and LV at end-diastole with addition of
extra slices as needed for complete coverage.
▪ Oblique sagittal parallel to the RVOT and
proximal MPA (Figure 13, Additional file 2).
▪ Parallel to the left ventricular outflow (LV
3-chamber view).
▪ Axial plane for imaging of the outflow tracts
and branch pulmonary arteries (all first studies,
optional thereafter).
Representative imaging parameters: echo time 1.7 ms;
repetition time 3.3 ms; flip angle 60°; sensitivity encod-
ing (SENSE) acceleration factor 2; field of view 260 mm;
matrix 160 × 160 reconstructed to 256 × 256; voxel size
1 . 6×1 . 8×6 - 8m mr e c o n s t r u c t e dt o1 . 0×1 . 0×6 - 8
mm; 30 reconstructed images per cardiac cycle.
￿ Magnetic resonance angiogram (MRA):N o n -
gated, breath-hold gadolinium-enhanced (0.2 mmol/
kg gadopentetate dimeglumine) 3-dimensional MRA
(all first studies, optional thereafter) (Figure 14).
Representative imaging parameters: echo time 1.5
ms; repetition time 4.5 ms; flip angle 40°; voxel size
0.95 × 1.06 × 2.4 mm reconstructed to 0.68 × 0.69 ×
1.2 mm; number of acquisitions 2; SENSE accelera-
tion factor 2; and acquisition time 20 s/acquisition.
Figure 10 Evaluation of ventricular size and function by
ECG-gated cine SSFP MR in repaired TOF: Right ventricular
2-chamber (vertical long-axis) plane. RA = right atrium; RV =
right ventricle; RVOT = right ventricular outflow tract.
Figure 9 Evaluation of ventricular size and function by
ECG-gated cine SSFP MR in repaired TOF: Left ventricular
2-chamber (vertical long-axis) plane.
Figure 11 Evaluation of biventricular size and function by ECG-
gated cine SSFP MR in repaired TOF: 4-chamber (horizontal long-
axis) plane.
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Page 12 of 24Figure 12 Evaluation of biventricular size and function by ECG-gated cine SSFP MR in repaired TOF: Ventricular short-axis. Note that
16 short-axis slices were required to fully cover the markedly dilated RV in this patient.
Figure 13 Evaluation of the right ventricular outflow tract
(RVOT) long-axis by ECG-gated cine SSFP MR. Along with the RV
2-chamber plane (Figure 10), this view demonstrates patency of the
RVOT and main pulmonary artery, presence or absence of
pulmonary valve tissue, and wall motion abnormalities.
Figure 14 Gadolinium-enhanced 3-dimensional magnetic
resonance angiography in a patient with repair TOF and a
giant aneurysm of the outflow patch.
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through cine phase contrast flow measurements
in the MPA (Figures 15, 16, 17, Additional file 3),
aorta,a n datrioventricular valves. Representative
imaging parameters: echo time 3.7 ms; repetition
time 5.9 ms; flip angle 15°; SENSE factor 2; field of
view 300 mm; matrix 192 × 192; voxel size 1.56 ×
1.56 × 6.0 mm reconstructed to 1.17 × 1.17 × 6.0
mm; 40 reconstructed images per cardiac cycle.
￿ Late gadolinium enhancement (LGE):E C G -
triggered, breath-hold, phase sensitive LGE imaging
performed 10-20 minutes after contrast administra-
tion in the following planes: ventricular short-axis
(Figure 18), LV 2-chamber, LV 3-chamber, RV
2-chamber, and 4-chamber. Areas suspected of LGE
(e.g., the thin walled RVOT free wall) are imaged in
orthogonal planes and with phase direction swapped
to facilitate recognition of artifacts.
In addition to the above, the following imaging
sequences are performed on a case-by-case basis:
￿ ECG-triggered, breath-hold cine SSFP in the short-
axis of the aortic root and ascending aorta (in
patients with dilated aortic root and ascending aorta).
￿ ECG-triggered, breath-hold turbo (fast) spin echo
sequence with blood suppression for imaging of
the outflow tracts and branch pulmonary arteries
in patients with image artifacts from metallic
implants.
￿ ECG-triggered, breathe-through cine phase con-
trast flow measurements in the branch pulmonary
arteries (when branch pulmonary artery stenosis is
identified).
Figure 15 Evaluation of pulmonary regurgitation (PR)
by ECG-gated cine phase contrast MR: The imaging plane is
placed perpendicular to the long-axis of the main pulmonary
artery (MPA).
Figure 16 Evaluation of pulmonary regurgitation (PR) by
ECG-gated cine phase contrast MR: Color-coded flow map of
the main pulmonary artery with the region of interest contour
shown at peak systole.
Figure 17 Evaluation of pulmonary regurgitation (PR) by ECG-
gated cine phase contrast MR: MPA flow rate (Y-axis) versus time
(X-axis). Flow above the baseline represents antegrade flow and
flow below the baseline represents retrograde (regurgitation) flow.
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ing 3-dimensional isotropic SSFP for evaluation of
the coronary arteries or as a substitute for contrast
magnetic resonance angiography.
In a cooperative patient the above protocol is typically
completed in 65-70 minutes.
Report Template
The importance of a structured report with an organized,
comprehensive structure that addresses all key elements
pertinent to clinical decision-making cannot be overem-
phasized. Key data reporting elements include:
￿ Anatomy of the RVOT and main and branch pul-
monary arteries with emphasis on obstruction and/
or dilatation or aneurysm formation.
￿ Biventricular size and function (global and
regional).
￿ Vessel dimensions: aortic root, ascending aorta,
MPA, right and left pulmonary arteries; if abnormal
(e.g., tricuspid regurgitation), diameters of the
atrioventricular valve.
￿ Flow measurements:
▪ Ascending aorta, MPA, right and left pulmon-
ary arteries
▪ Pulmonary valve regurgitation
▪ Other valve regurgitation
￿ Late gadolinium enhancement: presence, location,
and extent.
￿ Associated anomalies: systemic and pulmonary
veins, aortic arch sidedness and branching order.
An example of CMR report in a hypothetical patient
with repaired TOF is available in Additional File 4.
Offline analysis
Quantification of right and left ventricular size and func-
tion and blood flow is performed using dedicated software
available either from the manufacturers of MRI equip-
ment or from third party vendors. Measurements of
biventricular diastolic and systolic volumes and mass are
performed on ECG-gated cine SSFP images, which pro-
vide a high contrast between the blood pool (T2/T1 =
360/1200 = 0.3) and the myocardium (T2/T1 = 75/880 =
0.085) [115]. Accurate determination of ventricular
volume requires clear depiction of the blood-myocardial
boundary. Adjustments of the image brightness and con-
trast on the computer screen can facilitate visualization of
that boundary. By tracing the blood-endocardium bound-
ary, the slice’s blood pool volume is calculated as the pro-
duct of its cross-sectional area and thickness (which is
prescribed by the operator) (Figure 19). The left ventricu-
lar papillary muscles and the major trabeculations of the
RV (e.g., septal band) are excluded from the blood pool
and are considered part of the myocardium (Figure 19)
[46,116]. Ventricular volume is then determined by sum-
mation of the volumes of all slices. The process can be
repeated for each frame in the cardiac cycle to obtain a
continuous time-volume loop or may be performed only
on end-diastolic (maximal area) and end-systolic (minimal
area) frames to calculate diastolic and systolic volumes.
From this data one can calculate left and right ventricular
stroke volumes and ejection fractions. Since the patient’s
heart rate at the time of image acquisition is known, one
can calculate left and right ventricular outputs. Ventricular
mass is calculated by tracing the epicardial borders and
calculating the epicardial volume, subtracting the endocar-
dial volume, and multiplying the resultant muscle volume
by the specific gravity of the myocardium (1.05 g/mm
3).
Several approaches to measurements of biventricular
size and function have been reported. In general, these
can be divided into 2 broad categories: 1) methods that
rely on summation of discs (Simpson’s principle) [117];
and 2) methods that rely on modeling the chamber or
extrapolation of sparse data [118-120]. In the first
category each of the slices covering the ventricles is
contoured at least once at end-diastole (largest volume)
and at end-systole (smallest volume), requiring tracing
72 contours for biventricular volumes and mass. Some
Figure 18 Late gadolinium enhancement imaging in the
ventricular short-axis showing intense late hyperenhancement in
the RVOT (white arrow) and weak hyperenhancement in the
superior and inferior junctions between the interventricular septum
and the free wall (yellow arrows). The former represents scar tissue
and is associated with regional wall motion abnormalities. The latter
is a commonly observed finding in patients with repaired TOF and
its clinical importance is uncertain [42,85].
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axial or oblique long-axis planes [121,122]. The major
advantage of this approach, as compared with analysis
based on short-axis images, is the ease of determining
the planes of the mitral, tricuspid, and pulmonary
valves. This advantage is likely responsible for the
slightly higher reproducibility of measurements using
older software [122]. However, this approach limits eva-
luation of ventricular mass because the epicardial and
endocardial borders of the diaphragmatic wall are not
clearly defined. Recent development of techniques that
incorporate cross-references between long- and short-
axis images has greatly reduced the difficulty in deter-
mining valve plane on short-axis images (Figure 19)
[123]. Moreover, most reports on normal values as well
as the majority of the literature on ventricular size and
function in repaired TOF and other congenital and
acquired anomalies is based on analysis of short-axis
images [116,124,125].
In the second category either a formula based on a
geometrical model or extrapolation from sparse data are
used to generate ventricular volumes [118-120]. The
major advantage of this approach is shorter analysis
time but it is disadvantaged by reduced accuracy.
In our center ventricular volumes and mass are
measured from short-axis cine SSFP images [46]. Cross-
referencing the short-axis images with left and right
ventricular 2-chamber (vertical long-axis) and 4-
chamber (horizontal long-axis) cine SSFP facilitates
accurate determination of the atrioventricular and semi-
lunar valves planes during systole and diastole [123]. In
patients with repaired TOF particular attention should
be paid when determining the end-diastolic and end-
systolic phases of each ventricle. Given that conduction
delay is nearly universal in this population, peak RV
contraction typically lags after that of the LV by 1-3
cardiac phases (Figure 20). To optimize interstudy
reproducibility in patients followed longitudinally,
contours should be compared side-by-side with those
from previous studies. Saving the contour files along
with previous studies facilitates this comparison. On
average, total analysis time is ~30 minutes and decreases
with operator experience [123].
The technique for measuring blood flow is well estab-
lished [109]. PR fraction is calculated as retrograde flow
volume divided by antegrade flow volume in the proxi-
mal MPA using ECG-gated, free-breathing cine phase
contrast sequence obtained in the short-axis of the
proximal MPA (Figure 15 and 16) [46]. The operator
should adjust the imaging plane to avoid impingement
on the MPA by metallic artifacts from sternal wires and
implants. In addition to the PR fraction, both the ante-
grade and retrograde flow volumes should be reported
[126]. In the absence of a residual shunt, the net flow in
the MPA and ascending aorta should be nearly identical.
Similarly, in the absence of important tricuspid, mitral
or aortic valve regurgitation or shunt, left and right ven-
tricular stroke volume differential is primarily affected
by PR and calculation of PR fraction by the 2 methods
should be similar. In 15-20% of patients with repaired
TOF, however, residual shunt(s) and tricuspid and/or
aortic valve regurgitation are present, thus limiting the
use of these comparisons [95].
Figure 19 CMR assessment of biventricular volumes and mass
in repaired TOF. Cross-referencing between ventricular long- and
short-axis imaging planes aids determining inclusion of basal slices
in the ventricular volume analysis. When an operator selects a frame
on the short-axis grid, that location is highlighted on the linked
horizontal and vertical long axis images, allowing the operator to
determine the location of the slab relative to the atrioventricular
valves. Right lower panel: Examples of contour drawings on the left
and right ventricular endocardial and epicardial boundaries at the
base, mid-ventricular, and apical levels.
Figure 20 Plot of left and right ventricular volumes versus
time throughout the cardiac cycle in a patient with repaired
TOF. Note that minimal RV volume occurs 70 ms (2 cardiac phases)
after minimal LV volume.
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Most studies on the reproducibility of volumetric mea-
surements by CMR have focused on the LV and those
that included RV measurements were based on healthy
volunteers or patients with acquired heart disease
[124,127]. Few studies have addressed reproducibility of
volumetric measurements by CMR in patients with
repaired TOF [119,123,128]. Extrapolation of data from
healthy volunteers or from adults with acquired heart
disease to this group of patients may not be applicable
because the RV is typically dilated and hypertrophied,
the apical trabeculations are extensive, chamber geome-
try is abnormal with a prominent subtricuspid protru-
sion (the “shoulder” of the RV), the outflow patch is
dyskinetic, the plane of the pulmonary valve can be
unclear, and metallic artifacts from sternal wires or
other implants can obscure parts of the chamber.
Mooij et al. analyzed the intra- and inter-observer
variability of RV and LV size and function in 60
patients–20 with a normal RV, 20 with ASD or partially
anomalous pulmonary venous connection, and 20 with
repaired TOF [123]. In patients with repaired TOF
intraclass correlations were 0.966 for RV end-diastolic
volume, 0.932 for RV end-systolic volume, 0.817 for RV
ejection fraction, and 0.831 for RV mass. Theses results
are in agreement with those of Grothues et al. and Hud-
smith et al. [124,129]. Bland-Altman analyses showed no
systematic error in measurements related to the absolute
value of the measures. The reproducibility of the mea-
surements in patients with repaired TOF was not signifi-
cantly different from that in patients with normal RV or
with atrial septal defect. Moreover, the reproducibility of
most RV measurements did not differ significantly from
that of LV measurements. In practical terms, a differ-
ence of more than 34 ml/m2 (or 24%) was less than 5%
likely to be explained by interobserver variability.
CMR in Clinical Decision Making
CMR supports clinical decision making in patients with
repaired TOF by providing comprehensive anatomic and
functional information on postoperative cardiovascular
abnormalities. Especially important in these patients is
quantitative information on RV size, global and regional
RV function, LV size and function, myocardial scar,
RVOT aneurysm or obstruction, valve regurgitation
(especially helpful when quantified), residual intracardiac
shunts, and anatomic abnormalities of the pulmonary
arteries and aorta. CMR is increasingly being incorpo-
rated into clinical surveillance protocols once patients
with repaired TOF reach adolescence [109]. The combi-
nation of deteriorating echocardiographic windows,
nearly universal ability to tolerate the CMR examination
without sedation, and the comprehensive nature of the
CMR data has contributed to its broad acceptance in this
patient group. In addition to identifying anatomic and
functional abnormalities (Table 1), CMR’s ability to
quantify chamber size and function and measure blood
flow is especially helpful in clinical decision-making. For
example, CMR can identify and characterize branch pul-
monary artery stenosis (location, diameters, and length of
the narrow segment) followed by flow measurements in
the MPA and branch pulmonary arteries to quantify dif-
ferential pulmonary flow. A relatively mild discrepancy in
pulmonary blood flow (e.g., 40% flow to one lung) in the
absence of other indications for catheter or surgical inter-
vention will likely lead the clinician to recommend
expectant follow-up whereas severe discrepancy (e.g.,
15% flow to one lung) will likely lead to intervention.
Another example is identification of an atrial septal
defect followed by measurement of the pulmonary-to-
systemic flow ratio. A small shunt (e.g., pulmonary-to-
systemic flow ratio of 1.3) in a patient with mild PR (e.g.,
15% regurgitation fraction) and mild RV dilatation (e.g.,
120 ml/m
2) will likely lead the clinician to recommend
expectant follow-up whereas the same shunt in a patient
with moderate PR (e.g., 35% regurgitation fraction) and
RV dilatation (e.g., 145 ml/m
2) will prompt a discussion
about transcatheter device closure of the atrial septal
defect versus PVR and atrial septal defect closure.
Perhaps the most critical role of CMR in supporting
clinical decisions in patients with repaired TOF is deter-
mining when to replace or insert a pulmonary valve
[114]. As indicated before, the decision to insert a pul-
monary valve relies on clinical assessment of symptoms
and signs attributable to the cardiovascular system and
on measurements of PR, biventricular size and function,
shunt ratio, and several morphologic criteria (e.g.,
RVOT aneurysm, branch pulmonary artery stenosis,
severe aortic dilatation). Although some of the informa-
tion necessary for clinical decision support for PVR can
be obtained by other diagnostic modalities, CMR is best
suited to reliably provide most or all necessary informa-
tion [97,109,114]. For example, Doppler echocardiogra-
phy can distinguish between mild and severe PR [130],
3-dimensional echocardiography has the potential to
measure RV size and function [131], and tissue Doppler
and speckle tracking can provide information on RV
function [132]; RV size and function can also be mea-
sured by ECG-gated computed tomography and nuclear
ventriculography [63,133]; and cardiac catheterization
can provide information about pressure and shunt [134].
However, CMR provides the most comprehensive infor-
mation in a single noninvasive examination without
exposure to ionizing radiation [109]. Furthermore, the
reproducibility of CMR in measuring key parameters
necessary to support clinical decisions in repaired TOF
has been published whereas similar data from other
modalities in this group of patients is scant. Finally,
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various parameters used to decide when to replace or
insert a pulmonary valve are based on CMR data
[14,15,93-96,98,135,136].
Although CMR has become the reference standard
modality for follow-up of patients with repaired TOF,
specific patient groups require a multimodality approach
[137]. Table 4 summarizes several scenarios, in which a
combination of diagnostic modalities is required to sup-
port clinical decisions after TOF repair.
Future Directions
Research efforts in TOF aim to address the many facets
of the anomaly. Examples include elucidating the genetic
and developmental etiologies of the anomaly, refining
the initial surgical management to minimize late compli-
cations, defining markers of late adverse outcomes,
refining the criteria for PVR to optimize late outcomes,
and developing new tools to address the failing RV
before and after PVR. CMR plays an important role in
several of these research fronts. For example, CMR is
used to evaluate the function of tissue-engineered semi-
lunar valve implanted in the pulmonary position in
sheep [138]. This and similar technologies have the
potential to change the way TOF is repaired by allowing
the use of myocardial patches and bioengineered valves
derived from the patient’so w nc e l l st or e c o n s t r u c tt h e
RVOT. CMR contributes to this line of research by
allowing in-vivo evaluation of structure and function of
valves and ventricles.
Another research front in TOF is management of the
failing RV late after repair. It has recently been shown
that “standard” RV remodeling does not improve RV
function in this group of patients [95]. Our group has
conducted a series of experiments designed to develop a
computational modeling approach to determine the effi-
cacy and suitability of the various reconstructive options
for the RV [139,140]. Using patient-specific CMR data
of biventricular structure, deformation, and flow, RV-LV
computer models were constructed. These models
included fluid-structure interactions, two-layer RV-LV
structure, anisotropic material properties, fiber orienta-
tion, and active contraction. The models were designed
to simulate blood flow, ventricular motion, and stress-
strain distribution to evaluate the effect of different
remodeling procedures on RV function, and to seek an
optimal RV volume and patch design to improve post-
operative outcomes (Figure 21, Additional file 5). This
Table 4 Examples of scenarios requiring a multimodality diagnostic approach
Doppler
Echocardiography
Cardiac CT Nuclear
Scintigraphy
Cardiac
Catheterization
All patients ￿ Predicted RV pressure by TR
jet velocity
￿ Valve function and
interrogation of atrial and
ventricular septa by color
Doppler
RV hypertension with RVOT
obstruction or branch PA
stenosis
Predicted RV pressure by TR jet
velocity
Consider if (a) possible benefit from PA
balloon dilation and/or stent; or (b)
transcatheter PV implantation
RV hypertension without
RVOT obstruction or branch
PA stenosis
Assessment of peripheral branch PA
stenoses and pulmonary vascular
resistance
Branch PA stenosis without
reliable pulmonary flow
distribution by CMR
Lung
perfusion
scan
Branch PA stenosis with
≤35% flow to one lung
Consideration of balloon dilation with or
without stent placement
Contraindications to CMR or
large metallic artifacts
￿ Quantitative
evaluation of RV
size and
function
￿ Anatomy of
RVOT and
branch PAs
Age >40 years Coronary angiography before PVR
Secundum ASD with
systemic O2 saturation ≤92%
Hemodynamic assessment ± device
closure
ASD = atrial septal defect; PA = pulmonary artery; PV = pulmonary valve; PVR = pulmonary valve replacement; RV = right ventricle; RVOT = right ventricular
outflow tract; TR = tricuspid regurgitation.
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Page 18 of 24and similar research efforts may ultimately improve sur-
gical planning by identifying optimal individual solutions
to RV remodeling based on patient-specific, CMR-
derived computational models. Data from catheteriza-
tion-CMR studies may provide more detailed informa-
tion on RV mechanics (e.g., RV elastance or Emax,
ventricular-arterial coupling). Other advanced image
analysis techniques such as CMR speckle tracking may
overcome some of the limitations of RV tissue tagging
and provide further insight into RV-LV mechanics in
patients with repaired TOF (Figure 22) [141].
The most active clinical research efforts in repaired
TOF continue to focus on refining the indications for
PVR and developing better transcatheter and surgical
techniques to address PR and other late complications.
CMR plays a pivotal role in both fronts as the reference
standard imaging tool for morphologic and functional
assessments. As Table 3 demonstrates, past research
efforts were dominated by small retrospective studies.
Given that hard outcomes (e.g., death, ventricular tachy-
cardia) after PVR are uncommon and it is unclear
which surrogate outcomes properly reflect important
Figure 21 Computer model of right ventricular stress map
based on CMR data of a patient with repaired TOF. This and
similar models include fluid-structure interactions, two-layer RV-LV
structure, anisotropic material properties, fiber orientation, and
active contraction [139,140].
Figure 22 Tissue tracking of the ventricular myocardium (LV = left panel; RV = right panel) in a patient with repaired TOF. Analysis of
circumferential strain is performed in the ventricular short-axis plane using a commercial tissue tracking software package and custom-built
filters to modify the DICOM headers of the CMR datasets to allow them to be analyzed by the software package. The myocardium is divided
into 6 segments and circumferential strain (Y-axis;%) versus time (X-axis; milliseconds) is plotted for each segment. The time difference to peak
circumferential strain–a measure of ventricular synchrony–measured 83 ms in the LV and 389 ms in the RV, reflecting RV dyssynchrony.
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Page 19 of 24outcomes, it is highly unlikely that single-center studies
will provide meaningful answers. Undoubtedly, the next
phase of clinical research aimed at identifying the opti-
mal timing and method of restoring pulmonary valve
competence will require analysis of large databases that
include thousands patient years. This will require multi-
center collaboration and, preferably, standardized pro-
spectively acquired clinical and laboratory data,
including CMR. Although a randomized clinical trial
may appear to be an attractive research method to
define the optimal timing of PVR, the design of such
trial is challenging due to hurdles related to choice of
outcomes, statistical power, and recruitment. However,
once the state of knowledge in this area improves (e.g.,
identification of predictors of adverse outcomes after
PVR and meaningful surrogate outcomes), it is concei-
vable that specific hypotheses can be formulated and
then tested by a multicenter randomized trial. Undoubt-
edly, CMR will be an essential component of any such
study.
Conclusions
The pathophysiology of repaired TOF is complex.
Patients often tolerate the chronic volume load imposed
by pulmonary regurgitation and, in some patients, by
tricuspid regurgitation and residual intracardiac shunt
(s), for many years. In other patients, the pathophysiol-
ogy is further complicated by abnormalities in the pul-
monary arterial tree. Over time, however, the risks of
ventricular dysfunction, exercise intolerance, heart fail-
ure symptoms, arrhythmias, and death increase substan-
tially. CMR has evolved to become a crucial diagnostic
tool in this growing patient population. Key to optimal
use of CMR in these patients is a comprehensive ima-
ging protocol and implementation of steps to ensure
consistency and reproducibility of measurements.
Finally, CMR continues to play a key role in research
efforts directed at improving outcomes of patients with
tetralogy of Fallot.
Additional material
Additional file 1: Video clip of severe RV dilatation and dysfunction
after TOF repair. Cine SSFP imaging in a 37 year-old patient with
repaired TOF, severe pulmonary regurgitation, moderate tricuspid
regurgitation (arrow), and severe right ventricular dilatation (end-diastolic
volume index 386 ml/m
2) and dysfunction (ejection fraction 15%). This
patient who also exhibited severe heart failure symptoms had only
modest decrease in RV size and no improvement in RV function after
pulmonary valve replacement.
Additional file 2: Video clip of cine imaging of the RV long-axis.
Evaluation of the right ventricular outflow tract (RVOT) long-axis by ECG-
gated cine SSFP MR. Along with the RV 2-chamber plane (Figure 10), this
view demonstrates patency of the RVOT and main pulmonary artery,
presence or absence of pulmonary valve tissue, and wall motion
abnormalities.
Additional file 3: Video clip of pulmonary regurgitation after TOF
repair. Evaluation of pulmonary regurgitation (PR) by ECG-gated cine
phase contrast MR. Antegrade flow from the RV to the MPA is encoded
red and retrograde flow from the MPA to the RV (PR) is encoded blue.
Additional file 4: CMR report in repaired TOF. Example of CMR report
in a hypothetical patient with repaired TOF
Additional file 5: Video clip of computer modeling of the RV after
TOF repair. Computer model of right ventricular stress map based on
CMR data of a patient with repaired TOF.
Abbreviations
CMR: cardiovascular magnetic resonance; LGE: late gadolinium
enhancement; LV: left ventricle; PR: pulmonary regurgitation; PVR: pulmonary
valve replacement; RV: right ventricle; RVOT: right ventricular outflow tract;
TOF: tetralogy of Fallot.
Acknowledgements and Funding
This work was supported in part by the National Institutes of Health (NIH/
NHLBI 1 R01 HL089269-01A2) and by the Higgins Family Noninvasive
Cardiac Imaging Research Fund.
Competing interests
The author declares that they have no competing interests.
Received: 8 December 2010 Accepted: 20 January 2011
Published: 20 January 2011
References
1. Blalock A, Taussig HB: The surgical treatment of malformation of the
heart in which there is pulmonary stenosis or pulmonary atresia. JAMA
1945, 128:189-202.
2. Lillehei CW, Cohen M, Warden HE, Varco RL: The direct-vision
intracardiac correction of congenital anomalies by controlled cross
circulation; results in thirty-two patients with ventricular septal
defects, tetralogy of Fallot, and atrioventricularis communis defects.
Surgery 1955, 38:11-29.
3. Lillehei CW, Cohen M, Warden HE, Read RC, Aust JB, Dewall RA, Varco RL:
Direct vision intracardiac surgical correction of the tetralogy of Fallot,
pentalogy of Fallot, and pulmonary atresia defects; report of first ten
cases. Ann Surg 1955, 142:418-42.
4. Kirklin JW, Wallace RB, McGoon DC, DuShane JW: Early and late results
after intracardiac repair of Tetralogy of Fallot. 5-Year review of 337
patients. Ann Surg 1965, 162:578-89.
5. Bacha EA, Scheule AM, Zurakowski D, Erickson LC, Hung J, Lang P, Mayer JE
Jr, del Nido PJ, Jonas RA: Long-term results after early primary repair of
tetralogy of Fallot. J Thorac Cardiovasc Surg 2001, 122:154-61.
6. Parry AJ, McElhinney DB, Kung GC, Reddy VM, Brook MM, Hanley FL:
Elective primary repair of acyanotic tetralogy of Fallot in early infancy:
overall outcome and impact on the pulmonary valve. J Am Coll Cardiol
2000, 36:2279-83.
7. Pigula FA, Khalil PN, Mayer JE, del Nido PJ, Jonas RA: Repair of tetralogy of
Fallot in neonates and young infants. Circulation 1999, 100:II157-61.
8. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM,
McGoon DC, Kirklin JW, Danielson GK: Long-term outcome in patients
undergoing surgical repair of tetralogy of Fallot. N Engl J Med 1993,
329:593-9.
9. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W, Reichart B: Long-
term survival in patients with repair of tetralogy of Fallot: 36-year
follow-up of 490 survivors of the first year after surgical repair. J Am Coll
Cardiol 1997, 30:1374-83.
10. Geva T, Sandweiss BM, Gauvreau K, Lock JE, Powell AJ: Factors associated
with impaired clinical status in long-term survivors of tetralogy of Fallot
repair evaluated by magnetic resonance imaging. J Am Coll Cardiol 2004,
43:1068-74.
11. Gatzoulis MA, Walters J, McLaughlin PR, Merchant N, Webb GD, Liu P: Late
arrhythmia in adults with the mustard procedure for transposition of
great arteries: a surrogate marker for right ventricular dysfunction? Heart
2000, 84:409-15.
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 20 of 2412. Silka MJ, Hardy BG, Menashe VD, Morris CD: A population-based
prospective evaluation of risk of sudden cardiac death after operation
for common congenital heart defects. J Am Coll Cardiol 1998, 32:245-51.
13. Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon FP, Kay J,
Valente AM, Earing MG, Lui G, Gersony DR, Cook S, Ting JG, Nickolaus MJ,
Webb G, Landzberg MJ, Broberg CS: Arrhythmia burden in adults with
surgically repaired tetralogy of Fallot: a multi-institutional study.
Circulation 2010, 122:868-75.
14. Meijboom FJ, Roos-Hesselink JW, McGhie JS, Spitaels SE, van Domburg RT,
Utens LM, Simoons ML, Bogers AJ: Consequences of a selective approach
toward pulmonary valve replacement in adult patients with tetralogy of
Fallot and pulmonary regurgitation. J Thorac Cardiovasc Surg 2008,
135:50-5.
15. Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G: Optimal
timing for pulmonary valve replacement in adults after tetralogy of
Fallot repair. Am J Cardiol 2005, 95:779-82.
16. Buechel ER, Dave HH, Kellenberger CJ, Dodge-Khatami A, Pretre R, Berger F,
Bauersfeld U: Remodelling of the right ventricle after early pulmonary
valve replacement in children with repaired tetralogy of Fallot:
assessment by cardiovascular magnetic resonance. Eur Heart J 2005,
26:2721-7.
17. Ammash NM, Dearani JA, Burkhart HM, Connolly HM: Pulmonary
regurgitation after tetralogy of Fallot repair: clinical features, sequelae,
and timing of pulmonary valve replacement. Congenit Heart Dis 2007,
2:386-403.
18. Kuehne T, Saeed M, Reddy G, Akbari H, Gleason K, Turner D, Teitel D,
Moore P, Higgins CB: Sequential magnetic resonance monitoring of
pulmonary flow with endovascular stents placed across the pulmonary
valve in growing Swine. Circulation 2001, 104:2363-8.
19. Kuehne T, Saeed M, Gleason K, Turner D, Teitel D, Higgins CB, Moore P:
Effects of pulmonary insufficiency on biventricular function in the
developing heart of growing swine. Circulation 2003, 108:2007-13.
20. Siwek LG, Applebaum RE, Jones M, Clark RE: Acute control of pulmonary
regurgitation with a balloon “valve”. An experimental investigation.
J Thorac Cardiovasc Surg 1985, 90:404-9.
21. Cloan SD: Hemodynamic measurements, in Echocardiography in
pediatric and congenital heart disease: from fetus to adult.Edited by: Lai
WW, Mertens LL, Cohen MS, Geva T. Wiley-Blackwell: Philadelphia;
2010:63-75.
22. Kilner PJ, Balossino R, Dubini G, Babu-Narayan SV, Taylor AM, Pennati G,
Migliavacca F: Pulmonary regurgitation: the effects of varying pulmonary
artery compliance, and of increased resistance proximal or distal to the
compliance. Int J Cardiol 2009, 133:157-66.
23. Tverskaya MS, Mishnev OD, Raksha AP, Karpova VV, Sukhoparova VV,
Izmailova NS, Virganskii AO, Kadyrova M, Abdulkerimova NZ: Comparative
pathomorphological study of contractile myocardium under conditions
of increased left and right ventricular afterload. Bull Exp Biol Med 2004,
138:616-20.
24. Gruver EJ, Morgan JP, Stambler BS, Gwathmey JK: Uniformity of calcium
channel number and isometric contraction in human right and left
ventricular myocardium. Basic Res Cardiol 1994, 89:139-48.
25. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, Enriquez-
Sarano M: Outcomes after aortic valve replacement in patients with
severe aortic regurgitation and markedly reduced left ventricular
function. Circulation 2002, 106:2687-93.
26. Tornos MP, Olona M, Permanyer-Miralda G, Evangelista A, Candell J, Padilla F,
Soler Soler J: Heart failure after aortic valve replacement for aortic
regurgitation: prospective 20-year study. Am Heart J 1998, 136:681-7.
27. Bekeredjian R, Grayburn PA: Valvular heart disease: aortic regurgitation.
Circulation 2005, 112:125-34.
28. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G,
Sivananthan MU: Myocardial T1 mapping for detection of left ventricular
myocardial fibrosis in chronic aortic regurgitation: pilot study. AJR Am J
Roentgenol 2006, 187:W630-5.
29. Borer JS, Truter S, Herrold EM, Falcone DJ, Pena M, Carter JN, Dumlao TF,
Lee JA, Supino PG: Myocardial fibrosis in chronic aortic regurgitation:
molecular and cellular responses to volume overload. Circulation 2002,
105:1837-42.
30. Katz NM, Blackstone EH, Kirklin JW, Pacifico AD, Bargeron LM Jr: Late
survival and symptoms after repair of tetralogy of Fallot. Circulation 1982,
65:403-10.
31. Shimazaki Y, Blackstone EH, Kirklin JW: The natural history of isolated
congenital pulmonary valve incompetence: surgical implications. Thorac
Cardiovasc Surg 1984, 32:257-9.
32. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH,
Utens EM, Bogers AJ, Simoons ML: Excellent survival and low incidence of
arrhythmias, stroke and heart failure long-term after surgical ASD
closure at young age. A prospective follow-up study of 21-33 years. Eur
Heart J 2003, 24:190-7.
33. Pascotto M, Santoro G, Caso P, Cerrato F, Caso I, Caputo S, Bigazzi MC,
D’Andrea A, Russo MG, Calabro R: Global and regional left ventricular
function in patients undergoing transcatheter closure of secundum
atrial septal defect. Am J Cardiol 2005, 96:439-42.
34. Giardini A, Moore P, Brook M, Stratton V, Tacy T: Effect of transcatheter
atrial septal defect closure in children on left ventricular diastolic
function. Am J Cardiol 2005, 95:1255-7.
35. Salehian O, Horlick E, Schwerzmann M, Haberer K, McLaughlin P, Siu SC,
Webb G, Therrien J: Improvements in cardiac form and function after
transcatheter closure of secundum atrial septal defects. J Am Coll Cardiol
2005, 45:499-504.
36. Walker RE, Moran AM, Gauvreau K, Colan SD: Evidence of adverse
ventricular interdependence in patients with atrial septal defects. Am J
Cardiol 2004, 93:1374-7, A6.
37. Celik S, Ozay B, Dagdeviren B, Gorgulu S, Yildirim A, Uslu N, Ketenci B,
Eren M, Akgoz H, Demirtas M, Tezel T: Effect of patient age at surgical
intervention on long-term right ventricular performance in atrial septal
defect. Jpn Heart J 2004, 45:265-73.
38. Horvath KA, Burke RP, Collins JJ Jr, Cohn LH: Surgical treatment of adult
atrial septal defect: early and long-term results. J Am Coll Cardiol 1992,
20:1156-9.
39. Jategaonkar S, Scholtz W, Schmidt H, Horstkotte D: Percutaneous closure
of atrial septal defects: echocardiographic and functional results in
patients older than 60 years. Circ Cardiovasc Interv 2009, 2:85-9.
40. Dell’Italia LJ: The right ventricle: anatomy, physiology, and clinical
importance. Curr Probl Cardiol 1991, 16:653-720.
41. Geva T, Powell AJ, Crawford EC, Chung T, Colan SD: Evaluation of regional
differences in right ventricular systolic function by acoustic
quantification echocardiography and cine magnetic resonance imaging.
Circulation 1998, 98:339-45.
42. Wald RM, Haber I, Wald R, Valente AM, Powell AJ, Geva T: Effects of
regional dysfunction and late gadolinium enhancement on global right
ventricular function and exercise capacity in patients with repaired
tetralogy of Fallot. Circulation 2009, 119:1370-7.
43. Kiriazis H, Gibbs CL, Kotsanas G, Young IR: Mechanical and energetic
changes in short-term volume and pressure overload of rabbit heart.
Heart Vessels 1992, 7:175-88.
44. Lytrivi ID, Ko HH, Srivastava S, Norton K, Goldman J, Parness IA, Lai WW,
Nielsen JC: Regional differences in right ventricular systolic function as
determined by cine magnetic resonance imaging after infundibulotomy.
Am J Cardiol 2004, 94:970-3.
45. Davlouros PA, Kilner PJ, Hornung TS, Li W, Francis JM, Moon JC, Smith GC,
Tat T, Pennell DJ, Gatzoulis MA: right ventricular function in adults with
repaired tetralogy of Fallot assessed with cardiovascular magnetic
resonance imaging: detrimental role of right ventricular outflow
aneurysms or akinesia and adverse right-to-left ventricular interaction. J
Am Coll Cardiol 2002, 40:2044-52.
46. Samyn MM, Powell AJ, Garg R, Sena L, Geva T: Range of ventricular
dimensions and function by steady-state free precession cine MRI in
repaired tetralogy of Fallot: right ventricular outflow tract patch vs.
conduit repair. J Magn Reson Imaging 2007, 26:934-40.
47. Knauth AL, Gauvreau K, Powell AJ, Landzberg MJ, Walsh EP, Lock JE, del
Nido PJ, Geva T: Ventricular size and function assessed by cardiac MRI
predict major adverse clinical outcomes late after tetralogy of Fallot
repair. Heart 2008, 94:211-6.
48. Rebergen SA, Chin JG, Ottenkamp J, van der Wall EE, de Roos A:
Pulmonary regurgitation in the late postoperative follow-up of tetralogy
of Fallot. Volumetric quantitation by nuclear magnetic resonance velocity
mapping. Circulation 1993, 88:2257-66.
49. Helbing WA, Niezen RA, Le Cessie S, van der Geest RJ, Ottenkamp J, de
Roos A: Right ventricular diastolic function in children with pulmonary
regurgitation after repair of tetralogy of Fallot: volumetric evaluation by
magnetic resonance velocity mapping. J Am Coll Cardiol 1996, 28:1827-35.
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 21 of 2450. Helbing WA, de Roos A: Clinical applications of cardiac magnetic
resonance imaging after repair of tetralogy of Fallot. Pediatr Cardiol 2000,
21:70-9.
51. Greenberg SB, Crisci KL, Koenig P, Robinson B, Anisman P, Russo P:
Magnetic resonance imaging compared with echocardiography in the
evaluation of pulmonary artery abnormalities in children with tetralogy
of Fallot following palliative and corrective surgery. Pediatr Radiol 1997,
27:932-5.
52. Kurotobi S, Taniguchi K, Sano T, Naito H, Matsushita T, Kogaki S,
Ichikawa H, Ozono K: Determination of timing for reoperation in
patients after right ventricular outflow reconstruction. Am J Cardiol
2005, 95:1344-50.
53. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA,
Khan M, Ho SY, Pennell DJ, Gatzoulis MA: Ventricular fibrosis suggested by
cardiovascular magnetic resonance in adults with repaired tetralogy of
fallot and its relationship to adverse markers of clinical outcome.
Circulation 2006, 113:405-13.
54. van Straten A, Vliegen HW, Hazekamp MG, Lamb HJ, Ottenkamp J, Van der
Wall EE, De Roos A: Right ventricular diastolic function before and after
pulmonary valve replacement late after repair of tetralogy of Fallot assessed
by cardiac magnetic resonance imaging. J Am Coll Cardiol 2003, 41:491.
55. Sandor GG, Patterson MW, Tipple M, Ashmore PG, Popov R: Left ventricular
systolic and diastolic function after total correction of tetralogy of Fallot.
Am J Cardiol 1987, 60:1148-51.
56. Eroglu AG, Sarioglu A, Sarioglu T: Right ventricular diastolic function after
repair of tetralogy of Fallot: its relationship to the insertion of a
‘transannular’ patch. Cardiol Young 1999, 9:384-91.
57. Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN: Right
ventricular diastolic function 15 to 35 years after repair of tetralogy of
Fallot. Restrictive physiology predicts superior exercise performance.
Circulation 1995, 91:1775-81.
58. van der Hulst AE, Westenberg JJ, Kroft LJ, Bax JJ, Blom NA, de Roos A,
Roest AA: Tetralogy of fallot: 3D velocity-encoded MR imaging for
evaluation of right ventricular valve flow and diastolic function in
patients after correction. Radiology 2010, 256:724-34.
59. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J: Left ventricular
dysfunction is a risk factor for sudden cardiac death in adults late after
repair of tetralogy of fallot. J Am Coll Cardiol 2002, 40:1675-80.
60. Abd El Rahman MY, Hui W, Yigitbasi M, Dsebissowa F, Schubert S, Hetzer R,
Lange PE, Abdul-Khaliq H: Detection of left ventricular asynchrony in
patients with right bundle branch block after repair of tetralogy of
Fallot using tissue-Doppler imaging-derived strain. J Am Coll Cardiol 2005,
45:915-21.
61. Kondo C, Nakazawa M, Kusakabe K, Momma K: Left ventricular dysfunction
on exercise long-term after total repair of tetralogy of Fallot. Circulation
1995, 92:II250-5.
62. Hausdorf G, Hinrichs C, Nienaber CA, Schark C, Keck EW: Left
ventricular contractile state after surgical correction of tetralogy of
Fallot: risk factors for late left ventricular dysfunction. Pediatr
Cardiol 1990, 11:61-8.
63. Therrien J, Siu SC, McLaughlin PR, Liu PP, Williams WG, Webb GD:
Pulmonary valve replacement in adults late after repair of tetralogy of
fallot: are we operating too late? J Am Coll Cardiol 2000, 36:1670-5.
64. Adams CW: Bernheim effect (produced by an interventricular septal
aneurysm following septal infarction). Dis Chest 1966, 50:641-2.
65. Darsee JR, Mikolich JR, Walter PF, Schlant RC: Paradoxical rise in left
ventricular filling pressure in the dog during positive end-expiratory
pressure ventilation. A reversed Bernheim effect. Circ Res 1981,
49:1017-28.
66. Sanchez-Quintana D, Anderson RH, Ho SY: Ventricular myoarchitecture in
tetralogy of Fallot. Heart 1996, 76:280-6.
67. Tzemos N, Harris L, Carasso S, Subira LD, Greutmann M, Provost Y,
Redington AN, Rakowski H, Siu SC, Silversides CK: Adverse left ventricular
mechanics in adults with repaired tetralogy of Fallot. Am J Cardiol 2009,
103:420-5.
68. Ooi A, Moorjani N, Baliulis G, Keeton BR, Salmon AP, Monro JL, Haw MP:
Medium term outcome for infant repair in tetralogy of Fallot: Indicators
for timing of surgery. Eur J Cardiothorac Surg 2006, 30:917-22.
69. Lee C, Lee CN, Kim SC, Lim C, Chang YH, Kang CH, Jo WM, Kim WH:
Outcome after one-stage repair of tetralogy of Fallot. J Cardiovasc Surg
(Torino) 2006, 47:65-70.
70. Owen AR, Gatzoulis MA: Tetralogy of Fallot: Late outcome after repair
and surgical implications. Semin Thorac Cardiovasc Surg Pediatr Card Surg
Annu 2000, 3:216-226.
71. Alexiou C, Mahmoud H, Al-Khaddour A, Gnanapragasam J, Salmon AP,
Keeton BR, Monro JL: Outcome after repair of tetralogy of Fallot in the
first year of life. Ann Thorac Surg 2001, 71:494-500.
72. Oechslin EN, Harrison DA, Harris L, Downar E, Webb GD, Siu SS,
Williams WG: Reoperation in adults with repair of tetralogy of fallot:
indications and outcomes. J Thorac Cardiovasc Surg 1999, 118:245-51.
73. Redington AN: Determinants of short- and long-term outcome in the
surgical correction of tetralogy of Fallot. Curr Opin Pediatr 1993, 5:619-22.
74. Saul JP, Alexander ME: Preventing sudden death after repair of tetralogy
of Fallot: complex therapy for complex patients. J Cardiovasc
Electrophysiol 1999, 10:1271-87.
75. Kugler JD: Predicting sudden death in patients who have undergone
tetralogy of fallot repair: is it really as simple as measuring ECG
intervals? J Cardiovasc Electrophysiol 1998, 9:103-6.
76. Berul CI, Hill SL, Geggel RL, Hijazi ZM, Marx GR, Rhodes J, Walsh KA,
Fulton DR: Electrocardiographic markers of late sudden death risk in
postoperative tetralogy of Fallot children. J Cardiovasc Electrophysiol 1997,
8:1349-56.
77. Gatzoulis MA, Till JA, Somerville J, Redington AN: Mechanoelectrical
interaction in tetralogy of Fallot. QRS prolongation relates to right
ventricular size and predicts malignant ventricular arrhythmias and
sudden death. Circulation 1995, 92:231-7.
78. Bricker JT: Risks, markers, and causes. Sudden death and tetralogy of
Fallot. Circulation 1995, 92:158-9.
79. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marcon F,
Alexander ME, Walsh EP: Value of programmed ventricular stimulation
after tetralogy of fallot repair: a multicenter study. Circulation 2004,
109:1994-2000.
80. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C,
Rosenthal M, Nakazawa M, Moller JH, Gillette PC, Webb GD, Redington AN:
Risk factors for arrhythmia and sudden cardiac death late after repair of
tetralogy of Fallot: a multicentre study. Lancet 2000, 356:975-81.
81. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD,
Downar E, McLaughlin PR, Williams WG: Sustained ventricular tachycardia
in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol
1997, 30:1368-73.
82. Niezen RA, Helbing WA, van der Wall EE, van der Geest RJ, Rebergen SA, de
Roos A: Biventricular systolic function and mass studied with MR
imaging in children with pulmonary regurgitation after repair for
tetralogy of Fallot. Radiology 1996, 201:135-40.
83. Abd El Rahman MY, Abdul-Khaliq H, Vogel M, Alexi-Meskishvili V,
Gutberlet M, Lange PE: Relation between right ventricular enlargement,
QRS duration, and right ventricular function in patients with tetralogy of
Fallot and pulmonary regurgitation after surgical repair. Heart 2000,
84:416-20.
84. Doughan AR, McConnell ME, Lyle TA, Book WM: Effects of pulmonary
valve replacement on QRS duration and right ventricular cavity size late
after repair of right ventricular outflow tract obstruction. Am J Cardiol
2005, 95:1511-4.
85. Babu-Narayan SV, Goktekin O, Moon JC, Broberg CS, Pantely GA, Pennell DJ,
Gatzoulis MA, Kilner PJ: Late gadolinium enhancement cardiovascular
magnetic resonance of the systemic right ventricle in adults with
previous atrial redirection surgery for transposition of the great arteries.
Circulation 2005, 111:2091-8.
86. Therrien J, Siu SC, Harris L, Dore A, Niwa K, Janousek J, Williams WG,
Webb G, Gatzoulis MA: Impact of pulmonary valve replacement on
arrhythmia propensity late after repair of tetralogy of Fallot. Circulation
2001, 103:2489-94.
87. Discigil B, Dearani JA, Puga FJ, Schaff HV, Hagler DJ, Warnes CA,
Danielson GK: Late pulmonary valve replacement after repair of tetralogy
of Fallot. J Thorac Cardiovasc Surg 2001, 121:344-51.
88. Harrild DM, Berul CI, Cecchin F, Geva T, Gauvreau K, Pigula F, Walsh EP:
Pulmonary valve replacement in tetralogy of Fallot: impact on survival
and ventricular tachycardia. Circulation 2009, 119:445-51.
89. Caldarone CA, McCrindle BW, Van Arsdell GS, Coles JG, Webb G,
Freedom RM, Williams WG: Independent factors associated with longevity
of prosthetic pulmonary valves and valved conduits. J Thorac Cardiovasc
Surg 2000, 120:1022-30, discussion 1031.
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 22 of 2490. Bonhoeffer P, Boudjemline Y, Qureshi SA, Le Bidois J, Iserin L, Acar P,
Merckx J, Kachaner J, Sidi D: Percutaneous insertion of the pulmonary
valve. J Am Coll Cardiol 2002, 39:1664-9.
91. McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, Cheatham JP, Lock JE,
Vincent JA: Short- and medium-term outcomes after transcatheter
pulmonary valve placement in the expanded multicenter US melody
valve trial. Circulation 2010, 122:507-16.
92. Nordmeyer J, Lurz P, Tsang VT, Coats L, Walker F, Taylor AM,
Khambadkone S, de Leval MR, Bonhoeffer P: Effective transcatheter valve
implantation after pulmonary homograft failure: a new perspective on
the Ross operation. J Thorac Cardiovasc Surg 2009, 138:84-8.
93. Oosterhof T, van Straten A, Vliegen HW, Meijboom FJ, van Dijk AP,
Spijkerboer AM, Bouma BJ, Zwinderman AH, Hazekamp MG, de Roos A,
Mulder BJ: Preoperative thresholds for pulmonary valve replacement in
patients with corrected tetralogy of Fallot using cardiovascular magnetic
resonance. Circulation 2007, 116:545-51.
94. Frigiola A, Tsang V, Bull C, Coats L, Khambadkone S, Derrick G, Mist B,
Walker F, van Doorn C, Bonhoeffer P, Taylor AM: Biventricular response
after pulmonary valve replacement for right ventricular outflow tract
dysfunction: is age a predictor of outcome? Circulation 2008, 118:S182-90.
95. Geva T, Gauvreau K, Powell AJ, Cecchin F, Rhodes J, Geva J, del Nido P:
Randomized trial of pulmonary valve replacement with and without
right ventricular remodeling surgery. Circulation 2010, 122:S201-8.
96. Cheung EW, Wong WH, Cheung YF: Meta-analysis of pulmonary valve
replacement after operative repair of tetralogy of fallot. Am J Cardiol
2010, 106:552-7.
97. Vliegen HW, Van Straten A, De Roos A, Roest AA, Schoof PH,
Zwinderman AH, Ottenkamp J, Van Der Wall EE, Hazekamp MG: Magnetic
resonance imaging to assess the hemodynamic effects of pulmonary
valve replacement in adults late after repair of tetralogy of fallot.
Circulation 2002, 106:1703-7.
98. Henkens IR, van Straten A, Schalij MJ, Hazekamp MG, de Roos A, van der
Wall EE, Vliegen HW: Predicting outcome of pulmonary valve replacement
in adult tetralogy of Fallot patients. Ann Thorac Surg 2007, 83:907-11.
99. Gengsakul A, Harris L, Bradley TJ, Webb GD, Williams WG, Siu SC,
Merchant N, McCrindle BW: The impact of pulmonary valve replacement
after tetralogy of Fallot repair: a matched comparison. Eur J Cardiothorac
Surg 2007, 32:462-8.
100. Dave HH, Buechel ER, Dodge-Khatami A, Kadner A, Rousson V, Bauersfeld U,
Pretre R: Early insertion of a pulmonary valve for chronic regurgitation
helps restoration of ventricular dimensions. Ann Thorac Surg 2005,
80:1615-20, discussion 1620-1.
101. Yemets IM, Williams WG, Webb GD, Harrison DA, McLaughlin PR, Trusler GA,
Coles JG, Rebeyka IM, Freedom RM: Pulmonary valve replacement late
after repair of tetralogy of Fallot. Ann Thorac Surg 1997, 64:526-30.
102. Eyskens B, Reybrouck T, Bogaert J, Dymarkowsky S, Daenen W, Dumoulin M,
Gewillig M: Homograft insertion for pulmonary regurgitation after repair
of tetralogy of fallot improves cardiorespiratory exercise performance.
Am J Cardiol 2000, 85:221-5.
103. van Straten A, VliegenHW,Hazekamp MG, de RoosA: Right ventricular
function late after total repair oftetralogyof Fallot. Eur Radiol2005,15:702-7.
104. Oosterhof T, Mulder BJ, Vliegen HW, de Roos A: Corrected tetralogy of
Fallot: delayed enhancement in right ventricular outflow tract. Radiology
2005, 237:868-71.
105. Warner KG, O’Brien PK, Rhodes J, Kaur A, Robinson DA, Payne DD:
Expanding the indications for pulmonary valve replacement after repair
of tetralogy of fallot. Ann Thorac Surg 2003, 76:1066-71, discussion 1071-2.
106. Lurz P, Giardini A, Taylor AM, Nordmeyer J, Muthurangu V, Odendaal D,
Mist B, Khambadkone S, Schievano S, Bonhoeffer P, Derrick G: Effect of
altering pathologic right ventricular loading conditions by percutaneous
pulmonary valve implantation on exercise capacity. Am J Cardiol 2010,
105:721-6.
107. Graham TP Jr, Bernard Y, Arbogast P, Thapa S, Cetta F, Child J, Chugh R,
Davidson W, Hurwitz R, Kay J, Sanders S, Schaufelberger M: Outcome of
pulmonary valve replacements in adults after tetralogy repair: a multi-
institutional study. Congenit Heart Dis 2008, 3:162-7.
108. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE,
Landzberg MJ: Pregnancy outcomes in women with congenital heart
disease. Circulation 2006, 113:517-24.
109. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD:
Recommendations for cardiovascular magnetic resonance in adults with
congenital heart disease from the respective working groups of the
European Society of Cardiology. Eur Heart J 2010, 31:794-805.
110. Kang IS, Redington AN, Benson LN, Macgowan C, Valsangiacomo ER,
Roman K, Kellenberger CJ, Yoo SJ: Differential regurgitation in branch
pulmonary arteries after repair of tetralogy of Fallot: a phase-contrast
cine magnetic resonance study. Circulation 2003, 107:2938-43.
111. Babu-Narayan SV, Gatzoulis MA: Management of Adults with Operated
Tetralogy of Fallot. Curr Treat Options Cardiovasc Med 2003, 5:389-398.
112. Choe YH, Kang IS, Park SW, Lee HJ: MR imaging of congenital heart
diseases in adolescents and adults. Korean J Radiol 2001, 2:121-31.
113. de Roos A, Roest AA: Evaluation of congenital heart disease by magnetic
resonance imaging. Eur Radiol 2000, 10:2-6.
114. Geva T: Indications and timing of pulmonary valve replacement after
tetralogy of fallot repair. Semin Thorac Cardiovasc Surg Pediatr Card Surg
Annu 2006, 11-22.
115. Carr JC, Simonetti O, Bundy J, Li D, Pereles S, Finn JP: Cine MR
angiography of the heart with segmented true fast imaging with
steady-state precession. Radiology 2001, 219:828-34.
116. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU: Normal
human left and right ventricular dimensions for MRI as assessed by
turbo gradient echo and steady-state free precession imaging
sequences. J Magn Reson Imaging 2003, 17:323-9.
117. Alfakih K, Thiele H, Plein S, Bainbridge GJ, Ridgway JP, Sivananthan MU:
Comparison of right ventricular volume measurement between
segmented k-space gradient-echo and steady-state free precession
magnetic resonance imaging. J Magn Reson Imaging 2002, 16:253-8.
118. Hergan K, Schuster A, Fruhwald J, Mair M, Burger R, Topker M:
Comparison of left and right ventricular volume measurement using
the Simpson’s method and the area length method. Eur J Radiol 2008,
65:270-8.
119. Sheehan FH, Kilner PJ, Sahn DJ, Vick GW, Stout KK, Ge S, Helbing WA,
Lewin M, Shurman AJ, Buechel EV, Litt HI, Waiss MP: Accuracy of
knowledge-based reconstruction for measurement of right ventricular
volume and function in patients with tetralogy of Fallot. Am J Cardiol
2010, 105:993-9.
120. Moroseos T, Mitsumori L, Kerwin WS, Sahn DJ, Helbing WA, Kilner PJ,
Shurman A, Litt H, Sheehan FH: Comparison of Simpson’s method and
three-dimensional reconstruction for measurement of right ventricular
volume in patients with complete or corrected transposition of the
great arteries. Am J Cardiol 2010, 105:1603-9.
121. Strugnell WE, Slaughter RE, Riley RA, Trotter AJ, Bartlett H: Modified
RV short axis series–a new method for cardiac MRI measurement
of right ventricular volumes. J Cardiovasc Magn Reson 2005,
7:769-74.
122. Alfakih K, Plein S, Bloomer T, Jones T, Ridgway J, Sivananthan M:
Comparison of right ventricular volume measurements between axial
and short axis orientation using steady-state free precession magnetic
resonance imaging. J Magn Reson Imaging 2003, 18:25-32.
123. Mooij CF, de Wit CJ, Graham DA, Powell AJ, Geva T: Reproducibility of MRI
measurements of right ventricular size and function in patients with
normal and dilated ventricles. J Magn Reson Imaging 2008, 28:67-73.
124. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S: Normal
human left and right ventricular and left atrial dimensions using steady
state free precession magnetic resonance imaging. J Cardiovasc Magn
Reson 2005, 7:775-82.
125. Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ: Normal right-
and left ventricular volumes and myocardial mass in children measured
by steady state free precession cardiovascular magnetic resonance. J
Cardiovasc Magn Reson 2009, 11:19.
126. Wald RM, Redington AN, Pereira A, Provost YL, Paul NS, Oechslin EN,
Silversides CK: Refining the assessment of pulmonary regurgitation in
adults after tetralogy of Fallot repair: should we be measuring
regurgitant fraction or regurgitant volume? Eur Heart J 2009, 30:356-61.
127. Karamitsos T, Hudsmith L, Selvanayagama J, Neubauer S, Francis J: Operator
induced variability in left ventricular measurements with cardiovascular
magnetic resonance is improved after training. J Cardiovasc Mag Reson
2007, 9:777-783.
128. Beygui F, Furber A, Delepine S, Helft G, Metzger JP, Geslin P, Le Jeune JJ:
Routine breath-hold gradient echo MRI-derived right ventricular mass,
volumes and function: accuracy, reproducibility and coherence study.
Int J Cardiovasc Imaging 2004, 20:509-16.
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 23 of 24129. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ:
Interstudy reproducibility of right ventricular volumes, function, and
mass with cardiovascular magnetic resonance. Am Heart J 2004,
147:218-23.
130. Renella P, Aboulhosn J, Lohan DG, Jonnala P, Finn JP, Satou GM,
Williams RJ, Child JS: Two-dimensional and Doppler echocardiography
reliably predict severe pulmonary regurgitation as quantified by cardiac
magnetic resonance. J Am Soc Echocardiogr 2010, 23:880-6.
131. Iriart X, Montaudon M, Lafitte S, Chabaneix J, Reant P, Balbach T, Houle H,
Laurent F, Thambo JB: Right ventricle three-dimensional echography in
corrected tetralogy of fallot: accuracy and variability. Eur J Echocardiogr
2009, 10:784-92.
132. Mueller M, Rentzsch A, Hoetzer K, Raedle-Hurst T, Boettler P, Stiller B,
Lemmer J, Sarikouch S, Beerbaum P, Peters B, Vogt M, Vogel M, Abdul-
Khaliq H: Assessment of interventricular and right-intraventricular
dyssynchrony in patients with surgically repaired tetralogy of Fallot by
two-dimensional speckle tracking. Eur J Echocardiogr 2010, 11:786-92.
133. Raman SV, Cook SC, McCarthy B, Ferketich AK: Usefulness of multidetector
row computed tomography to quantify right ventricular size and
function in adults with either tetralogy of Fallot or transposition of the
great arteries. Am J Cardiol 2005, 95:683-6.
134. Norgard G, Rosland GA, Segadal L, Vik-Mo H: Hemodynamic status in
repaired tetralogy of Fallot assessed by Doppler echocardiography and
cardiac catheterization. Comparisons with healthy subjects and
elucidation of factors associated with cardiorespiratory function. Scand J
Thorac Cardiovasc Surg 1993, 27:41-8.
135. Wald RM, Lyseggen E, Oechslin EN, Webb GD, Silversides CK: Variability in
surgical referral patterns for pulmonary valve replacement in adults with
repaired tetralogy of fallot. Congenit Heart Dis 2009, 4:231-8.
136. van der Wall EE, Mulder BJ: Pulmonary valve replacement in patients with
tetralogy of Fallot and pulmonary regurgitation: early surgery similar to
optimal timing of surgery? Eur Heart J 2005, 26:2614-5.
137. Prakash A,PowellAJ, GevaT:Multimodalitynoninvasive imaging for
assessment ofcongenitalheart disease. Circ Cardiovasc Imaging2010, 3:112-25.
138. Gottlieb D, Kunal T, Emani S, Aikawa E, Brown DW, Powell AJ, Nedder A,
Engelmayr GC, Melero-Martin JM, Sacks MS, Mayer JE Jr: In vivo monitoring
of function of autologous engineered pulmonary valve. J Thorac
Cardiovasc Surg 2010, 139:723-31.
139. Tang D, Yang C, Geva T, Del Nido PJ: Patient-specific MRI-based 3D FSI
RV/LV/patch models for pulmonary valve replacement surgery and
patch optimization. J Biomech Eng 2008, 130:041010.
140. Tang D, Yang C, Geva T, del Nido PJ: Image-based patient-specific
ventricle models with fluid-structure interaction for cardiac function
assessment and surgical design optimization. Progress in Pediatric
Cardiology 2010, 30:51-62.
141. Ortega M, Triedman JK, Geva T, Harrild DM: LV dyssynchrony measured by
MRI speckle tracking is associated with VT and death in repaired
tetralogy of Fallot. Circulation 2009, 120:S575.
142. Bove EL, Kavey RE, Byrum CJ, Sondheimer HM, Blackman MS, Thomas FD:
Improved right ventricular function following late pulmonary valve
replacement for residual pulmonary insufficiency or stenosis. J Thorac
Cardiovasc Surg 1985, 90:50-5.
143. Ilbawi MN, Idriss FS, DeLeon SY, Muster AJ, Berry TE, Paul MH: Long-term
results of porcine valve insertion for pulmonary regurgitation following
repair of tetralogy of Fallot. Ann Thorac Surg 1986, 41:478-82.
144. Kanter KR, Budde JM, Parks WJ, Tam VK, Sharma S, Williams WH, Fyfe DA:
One hundred pulmonary valve replacements in children after relief of
right ventricular outflow tract obstruction. Ann Thorac Surg 2002,
73:1801-6, discussion 1806-7.
145. Oosterhof T, Meijboom FJ, Vliegen HW, Hazekamp MG, Zwinderman AH,
Bouma BJ, van Dijk AP, Mulder BJ: Long-term follow-up of homograft
function after pulmonary valve replacement in patients with tetralogy of
Fallot. Eur Heart J 2006, 27:1478-84.
146. Kogon B, Plattner C, Kirshbom P, Kanter K, Leong T, Lyle T, Jennings S,
McConnell M, Book W: Risk factors for early pulmonary valve
replacement after valve disruption in congenital pulmonary stenosis and
tetralogy of Fallot. J Thorac Cardiovasc Surg 2009, 138:103-8.
147. Lindsey CW, Parks WJ, Kogon BE, Sallee D, Mahle WT: Pulmonary valve
replacement after tetralogy of Fallot repair in preadolescent patients.
Ann Thorac Surg 2010, 89:147-51.
148. van Straten A, Vliegen HW, Lamb HJ, Roes SD, van der Wall EE,
Hazekamp MG, de Roos A: Time course of diastolic and systolic function
improvement after pulmonary valve replacement in adult patients with
tetralogy of Fallot. J Am Coll Cardiol 2005, 46:1559-64.
doi:10.1186/1532-429X-13-9
Cite this article as: Geva: Repaired tetralogy of Fallot: the roles of
cardiovascular magnetic resonance in evaluating pathophysiology and
for pulmonary valve replacement decision support. Journal of
Cardiovascular Magnetic Resonance 2011 13:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Geva Journal of Cardiovascular Magnetic Resonance 2011, 13:9
http://www.jcmr-online.com/content/13/1/9
Page 24 of 24